Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs (1-2-3)
This study has been completed.
First Received: November 13, 2008   Last Updated: November 28, 2008   History of Changes
Sponsored by: Novo Nordisk
Information provided by: Novo Nordisk
ClinicalTrials.gov Identifier: NCT00791895
  Purpose

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.


Condition Intervention Phase
Diabetes Mellitus, Type 2
 Drug: biphasic insulin aspart 30
 Phase IV

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

Resource links provided by NLM:

MedlinePlus related topics: Diabetes
Drug Information available for: Insulin Insulin aspart
U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • Percentage of subjects achieving HbA1c below 6.5% [ Time Frame: after 16, 32 and 48 weeks, respectively ]

Enrollment: 102
Study Start Date: June 2003
Study Completion Date: November 2004
Arms Assigned Interventions
A: Experimental Drug: biphasic insulin aspart 30
Treat-to-target dose titration scheme

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes mellitus for at least 12 months
  • HbA1c: 7.5-10.0%
  • An antidiabetic regimen that has been stable for at least 3 months
  • Able and willing to perform SMBG testing as per protocol

Exclusion Criteria:

  • Use of any insulin preparations other than NPH or glargine within the past 6 months
  • Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or judged to be using inadequate contraceptive measures (adequate contraceptive measures includes: sterilization, intrauterine devices, oral contraceptives, or consistent use of barrier methods)
  • Known or suspected allergy to trial product or agents related to trial product
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00791895

Locations
United States, Arizona
Novo Nordisk Clinical Trial Call Center
Phoenix, Arizona, United States, 85006
United States, California
Novo Nordisk Clinical Trial Call Center
La Jolla, California, United States, 92093-0831
Novo Nordisk Clinical Trial Call Center
San Deigo, California, United States, 92103
United States, Florida
Novo Nordisk Clinical Trial Call Center
Deland, Florida, United States, 32720
United States, Nebraska
Novo Nordisk Clinical Trial Call Center
Omaha, Nebraska, United States, 68131
United States, New York
Novo Nordisk Clinical Trial Call Center
Albany, New York, United States, 12206
United States, Ohio
Novo Nordisk Clinical Trial Call Center
Cleveland, Ohio, United States, 44115
United States, Oregon
Novo Nordisk Clinical Trial Call Center
Medford, Oregon, United States, 97504
United States, Tennessee
Novo Nordisk Clinical Trial Call Center
Memphis, Tennessee, United States, 38119
United States, Texas
Novo Nordisk Clinical Trial Call Center
Dallas, Texas, United States, 75231
Novo Nordisk Clinical Trial Call Center
Houston, Texas, United States, 77030
United States, Utah
Novo Nordisk Clinical Trial Call Center
Ogden, Utah, United States, 84403
United States, Washington
Novo Nordisk Clinical Trial Call Center
Renton, Washington, United States, 98057
United States, Wisconsin
Novo Nordisk Clinical Trial Call Center
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Elizabeth Hillier Novo Nordisk
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Novo Nordisk A/S ( Public Access to Clinical Trials )
Study ID Numbers: BIASP-2174
Study First Received: November 13, 2008
Last Updated: November 28, 2008
ClinicalTrials.gov Identifier: NCT00791895     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Hypoglycemic Agents
Metabolic Diseases
Diabetes Mellitus, Type 2
Insulin, Asp(B28)-
Diabetes Mellitus
 Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder
Insulin

Additional relevant MeSH terms:
Hypoglycemic Agents
Metabolic Diseases
Physiological Effects of Drugs
Diabetes Mellitus, Type 2
Insulin, Asp(B28)-
 Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions
Insulin

ClinicalTrials.gov processed this record on September 10, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services